Scott Benner Scott Benner

Arden’s Endometriosis Surgery: “All of My Years of Pain Had a Reason”

Endometriosis, Type 1 Diabetes, and Finally Getting an Answer | Juicebox Podcast
From the Juicebox Blog

Endometriosis, Type 1 Diabetes, and Finally Getting an Answer

Arden was diagnosed with type 1 diabetes at two. After years of pain, excision surgery found endometriosis on her uterus, ovaries, rectum, and colon. This is her post, in her own words.

Arden Benner · November 2026

Arden shared this on Instagram on the day of her surgery. It appears here with her permission, as she wrote it. See the original post on Instagram.

Today, I underwent laparoscopic excision surgery for endometriosis. During surgery, they found endo on my uterus, ovaries, rectum, and colon. They also discovered that my colon was adhered to my pelvic wall. Suddenly, all of my years of pain had a reason behind them.

I was diagnosed with type 1 diabetes at two years old. Thyroid problems at 12. Iron deficiencies and debilitating periods by 15. PCOS in high school. I’ve spent so much of my life in doctors’ offices, emergency rooms, and hospital beds, searching for explanations and trying to understand why my body feels like it’s betraying me.

I thought it was all normal, ya know, parts of being a woman. The joint pain. The bloating. The nausea. The headaches. The exhaustion that sleep doesn’t fix. The brain fog that makes you feel like you’re losing your mind. The stomach issues, urinary symptoms, painful sex, acne, and weight fluctuations. The pain in my ribs, shoulders, back, knees, and ankles. Periods that don’t just hurt, but completely take over your life.

“Suddenly, all of my years of pain had a reason behind them.”

Arden Benner

After enough pain, doctors, hospitals, medications and the hate I started to feel towards my body, I decided it was enough. Today I got to see there was a physical explanation for the pain I’ve been experiencing most of my life.

Chronic illness is hard for most people to understand, it takes away your life. You cancel plans. You miss experiences. You lose relationships, opportunities, and parts of yourself. You watch other people your age live so effortlessly while you’re calculating whether you’ll have enough energy to make it through the day. And at some point, you start to resent the body that’s keeping you alive.

However, as much as I hate this stupid body… It’s gotten me through every diagnosis, every hospital visit, every needle, every sleepless night, and every day I thought I couldn’t do it anymore. It’s not perfect. It hurts. It changes. It makes my life a hell of a lot harder than I’d like it to be.

But it’s mine. And it’s pretty fucking cool.

P.S. Thanks mom and dad, I love you.

See the original post on Instagram →

A note for readers. This is one person’s experience, shared in her own words. It is not medical advice and is not meant to diagnose anything. If any of this sounds familiar, bring it to your doctor — and keep asking until you get an answer that makes sense.

Listen to the Juicebox Podcast

Conversations about diabetes, five days a week, since 2015.

The content on this site is for educational purposes only and is not medical advice.
Read the full disclaimer
© 2007–2026 Juicebox Podcast. All rights reserved.
Read More
Scott Benner Scott Benner

Dexcom’s Type 2 Report: The Survey, and the Trial Behind It

Dexcom’s Type 2 Report: The Survey, and the Trial Behind It | Juicebox Podcast
From the Juicebox Blog

Dexcom’s Type 2 Report: The Survey, and the Trial Behind It

A new survey of 2,502 people with Type 2 diabetes finds most know little about CGM. The stronger evidence on whether CGM helps them comes from a randomized trial the report cites.

Scott Benner · September 2026

Dexcom released its 2026 “State of Type 2” report on September 28 at the European Association for the Study of Diabetes meeting in Milan. It is a survey. In April 2026, Dexcom partnered with the research firm HarrisX to poll 2,502 adults with Type 2 diabetes and 888 clinicians across eight countries, including the United States.

The headline finding is a knowledge gap. Only 33% of people with Type 2 said they know what a CGM is and how it could help. 28% said they do not know what one is at all. And 72% did not know that GLP-1 medications and CGM can be used together.

Disclosure: Dexcom sponsors the Juicebox Podcast. That is a reason to read this post, and the report, with care. A company survey measures what people say. It is not evidence that CGM works. For that, the report points to other research, covered below.

What the survey measured

Among GLP-1 users in the survey, 58% said they pair the medication with a CGM. Among GLP-1 users who are not on insulin, the report puts that figure at 27%.

Clinicians named cost. In the U.S., 90% cited coverage or reimbursement as a barrier to CGM, compared with 53% across the other seven countries. About one in four U.S. respondents with Type 2 said they had trouble paying for diabetes medication or supplies in the past year.

The roughly 300 current CGM users in the survey were positive: 94% said they manage their diabetes more independently, and 91% said they use the data to make treatment decisions. Those are self-reports from people who chose a CGM and kept wearing it. The survey says nothing about people who tried one and stopped.

What the trials show

The stronger evidence is the CONNECT trial, which the report cites. CONNECT randomly assigned 283 adults with Type 2 who do not use insulin, at 22 U.S. primary care practices, to either a Dexcom G7 or routine care with a fingerstick meter for 26 weeks. Dexcom sponsored the trial.

Participants started at an average A1C of 8.8%. A1C fell 1.6 points in the CGM group and 0.7 points with routine care, a 0.9-point difference. Time in range (70–180 mg/dL) was 62% with CGM and 41% without. The results were presented as a conference abstract at the American Diabetes Association’s Scientific Sessions in June 2026. A full peer-reviewed paper could not be found as of this writing.

A separate study in JAMA Network Open looked back at insurance and medical records for 9,258 adults with Type 2. People who wore a CGM more than 270 days a year saw A1C fall 1.52 points over 12 months, compared with 0.63 points in matched people who did not use one. That is an association, not proof of cause. Three of the study’s seven authors work for Roche Diagnostics, a diabetes device maker.

Compare the evidence

Three sources, three kinds of evidence

Tap a source. The bars are an editorial rating of evidence depth, not how well CGM works.

Editorial evidence depthRandomized trial

CONNECT trial

A randomized trial of a Dexcom G7 versus routine care in adults with Type 2 not on insulin. Sponsored by Dexcom; reported so far as a conference abstract.

  • 283 adults, 22 U.S. primary care practices, 26 weeks.
  • A1C fell 1.6 points with CGM vs. 0.7 with routine care: a 0.9-point difference.
  • Time in range 62% with CGM vs. 41% with routine care.

Scale: 3 = randomized trial · 2 = observational study of real-world records · 1 = survey of self-reported views.

What is still open

CONNECT answers a narrow question: over six months in primary care, does adding a CGM lower A1C for people with Type 2 who are not on insulin? It does not yet show whether the drop holds past six months. A six-month extension is underway, according to the ADA. It also says nothing yet about complications. And participants knew which group they were in, which is unavoidable when the treatment is a device.

The ADA’s 2026 Standards of Care already recommend CGM for people with diabetes on “any diabetes treatment where CGM helps in management.” That part of the recommendation is graded C, below the A given for people on insulin. Randomized evidence like CONNECT is what could move that grade. Whether it does is up to the ADA.

How the survey was run

HarrisX surveyed 2,502 adults with Type 2 and 888 clinicians in April 2026, roughly 310 patients and 110 clinicians per country: Germany, Italy, Japan, Poland, Saudi Arabia, Sweden, the United Kingdom, and the United States. Clinicians were split about evenly between doctors and nurses.

The report does not say how respondents were recruited. Its unreferenced figures are cited as “Dexcom Data on File, 2026,” meaning the underlying data has not been published for outside review.

What this means for this community

Most of the Juicebox audience lives with Type 1 or cares for someone who does, and CGM is common there. This report is about the much larger Type 2 population, and plenty of listeners have a parent, partner, or friend in it. The survey’s clearest signal is how many people with Type 2 say they know little about CGM.

The trial evidence for CGM in Type 2 without insulin is newer and still maturing. For anyone with Type 2 who is curious, the questions for their doctor are whether a CGM fits their treatment and whether their insurance covers it. This post is for education only. Talk with your doctor before making any changes to your care.

Sources. The Dexcom report and press release were used for the survey figures only. Clinical claims are cited to the underlying research.

Survey. Dexcom. State of Type 2 Report: Global Access and Attitudes to Diabetes Technology, 2026. Conducted with HarrisX, April 2026; Dexcom Data on File. Report page · Press release, September 28, 2026.

Randomized trial. Oser T, et al. CGM for Adults with Type 2 Diabetes Not on Insulin Therapy: The CONNECT Randomized Controlled Trial. Diabetes 2026;75(Suppl 1):1170-OR, conference abstract. Sponsored by Dexcom. Additional figures: American Diabetes Association; Cleveland Clinic Journal of Medicine.

Records study. Hirsch IB, Garg SK, Repetto E, et al. Continuous Glucose Monitoring Frequency and Glycemic Control in People With Type 2 Diabetes. JAMA Netw Open 2025;8(10):e2539278. Retrospective, propensity-matched. Three authors affiliated with Roche Diagnostics.

Guideline. American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2026. Diabetes Care 2026;49(Suppl 1), recommendation 7.15.

How to read this evidence. A randomized trial is the strongest design here, but one sponsored trial reported as an abstract is an early result. The records study shows an association, not cause: people who keep wearing a CGM may differ in other ways from people who do not. The survey reports opinions and self-described behavior only.

This post is for educational purposes only and is not medical advice. Nothing here is a recommendation to start, stop, or change any device or medication.

Listen to the Juicebox Podcast

Conversations about diabetes, five days a week, since 2015.

The content on this site is for educational purposes only and is not medical advice.
Read the full disclaimer
© 2007–2026 Juicebox Podcast. All rights reserved.
Read More
Scott Benner Scott Benner

FDA Approves Kerendia for Kidney Disease in Type 1 Diabetes

FDA Approves Kerendia for Kidney Disease in Type 1 Diabetes | Juicebox Podcast
From the Juicebox Blog · Research News

FDA Approves Kerendia for Kidney Disease in Type 1 Diabetes

Bayer’s finerenone is now approved for adults with chronic kidney disease tied to type 1 diabetes. The approval rests on one six-month trial that measured a lab marker, not kidney failure.

Scott Benner · September 2026

On September 16, 2026, the FDA approved Kerendia (finerenone), a once-daily pill from Bayer, for adults with chronic kidney disease associated with type 1 diabetes. Bayer calls it the first new treatment for this group in more than 30 years.

The approval rests on one randomized trial, FINE-ONE, published in the New England Journal of Medicine in March 2026. That trial did not count kidney failure. It measured albumin in the urine, a lab marker of kidney damage. The label, as quoted by Bayer, says the drug reduces that marker, which is expected to lower the risk of kidney decline and end-stage kidney disease.

The drug itself isn’t new. According to Bayer, it has been approved since 2021 for kidney disease in type 2 diabetes, and since 2025 for a type of heart failure. What changed is who it’s approved for.

How it got here

Three decades, four stops

Tap a stage to see how it developed.

A randomized trial of 409 people with type 1 diabetes and kidney disease, published in NEJM in 1993, found the ACE inhibitor captopril cut the risk of serum creatinine doubling by 48% compared with placebo. Drugs that block this hormone system (ACE inhibitors and ARBs) are still standard care, per the FINE-ONE design paper.

What FINE-ONE found

FINE-ONE enrolled 242 adults with type 1 diabetes, reduced kidney function (eGFR 25 to under 90), and elevated urine albumin (a urine albumin-to-creatinine ratio, or UACR, of 200 to under 5,000 mg/g). Everyone was already taking an ACE inhibitor or an ARB. Participants were randomized to finerenone, 10 or 20 mg a day depending on kidney function, or placebo.

Worth naming plainly: Bayer funded the trial and makes the drug, and several of the paper’s authors are Bayer employees.

The result: over six months, urine albumin fell 25% more with finerenone than with placebo (95% CI for the ratio, 0.65 to 0.87). Bayer’s release quotes the same comparison at single time points instead, 22% at month 3 and 28% at month 6. The trial tracked three things worth knowing. Tap each.

FINE-ONE · randomized trial · 242 adults

Three results from one trial

Tap a tab. Every number here is from the published trial or Bayer’s release, as noted.

The main result

Urine albumin

The primary endpoint: relative change in the urine albumin-to-creatinine ratio over six months.

  • Median UACR went from 574.6 to 373.5 in the finerenone group, and from 506.4 to 475.6 in the placebo group (NEJM).
  • Compared with placebo, finerenone produced a 25% greater reduction (geometric mean ratio 0.75; 95% CI 0.65 to 0.87) (NEJM).
  • The 34% and 12% drops are within-group changes from baseline. They are not the treatment effect on their own.

What nobody knows yet

FINE-ONE shows finerenone lowers albumin in people with type 1 diabetes. On its own, it does not show fewer cases of kidney failure. That link is borrowed from the type 2 trials. There are two fair ways to read that.

VIEW 1 The bridge is reasonable

In type 2 diabetes, FIDELIO-DKD (5,734 people, also Bayer-funded) found fewer combined kidney events with finerenone over a median 2.6 years: 17.8% versus 21.1% on placebo. The FINE-ONE design paper says regulators agreed urine albumin could bridge that evidence to type 1, as long as set criteria were met.

VIEW 2 A stand-in is still a stand-in

Six months and 242 people is too short and too small to count kidney failure, dialysis, or deaths. What is known about safety in type 1 also comes from those six months. No long-term outcome trial of finerenone in type 1 diabetes has reported.

Both can be true at once. The approval follows a logic regulators agreed to in advance, and the long-term answer in type 1 is still open.

The approval rests on a lab value moving in the right direction. That is a reasonable bet, and it is still a bet.

An editorial observation

What this means for people with type 1

Kidney disease is a common complication. Bayer’s release puts it at roughly 20 to 30% of people in the U.S. with type 1 diabetes, and the FINE-ONE design paper says up to 40% develop it despite guideline-recommended treatment.

Kerendia is not an insulin and is not a blood sugar medication. The approval covers adults who already have kidney disease tied to type 1. The trial tested it on top of an ACE inhibitor or ARB, not in place of one, and it enrolled adults only.

Dr. Janet McGill of Washington University School of Medicine, the final author on the FINE-ONE paper, said in Bayer’s release that this group has had “limited options to address the risk of kidney disease progression.”

For anyone following their kidney health, the two lab numbers in this story are urine albumin (UACR) and eGFR. Whether any medication makes sense for a specific person, and how potassium would be watched, is a conversation to have with a doctor.

Sources. Bayer’s press release (Business Wire, September 16, 2026) was used for the approval date, label wording, prevalence estimate, and the McGill quote. Trial findings are cited to the published research:

FINE-ONE results. Heerspink HJL, Birkenfeld AL, Cherney DZI, et al. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 394(10):947–957, March 2026. Randomized, double-blind, placebo-controlled phase 3 trial, n=242. Funded by Bayer. NCT05901831.

FINE-ONE design. Heerspink HJL, et al. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease. Diabetes Res Clin Pract 204:110908, October 2023. Several authors are Bayer employees.

Type 2 outcomes. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD). N Engl J Med 383:2219–2229, 2020. Randomized trial, n=5,734. Funded by Bayer.

1993 captopril trial. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456–1462, 1993. Randomized trial, n=409.

Press release. Bayer, via Business Wire, September 16, 2026. Company statement, not peer reviewed.

How to read this evidence. FINE-ONE is a randomized trial, the strongest study design, but it is one trial, industry-funded, six months long, and its main endpoint is a lab marker rather than kidney failure. The kidney-outcome evidence for finerenone comes from people with type 2 diabetes. The approval covers adults with chronic kidney disease associated with type 1 diabetes; it does not cover children, and finerenone is not a treatment for blood sugar.

This post is for educational purposes only and is not medical advice. Nothing here is a recommendation to start, stop, or change any medication. Talk with your doctor before making any changes to your care.

Listen to the Juicebox Podcast

Conversations about diabetes, five days a week, since 2015.

The content on this site is for educational purposes only and is not medical advice.
Read the full disclaimer
© 2007–2026 Juicebox Podcast. All rights reserved.
Read More
Scott Benner Scott Benner

An AI-designed drug just reached Phase 3

An AI-Designed Drug Just Reached Phase 3 | Juicebox Podcast
From the Juicebox Blog

An AI-designed drug just reached Phase 3

It treats a lung disease, not diabetes. It is still the clearest look yet at what artificial intelligence has changed about how new drugs get made — and what it hasn’t.

Scott Benner · September 2026
Short on time, or sharing this with someone?

On September 9, 2026, the first patient was dosed in a Phase 3 trial of a drug called rentosertib. The trial, GENESIS-IPF-3, is planned to enroll 320 people with idiopathic pulmonary fibrosis across 47 centers in China, dosed once daily for 52 weeks, with the annual rate of lung-function decline as its primary endpoint. What makes it unusual is where the drug came from. AI systems were used both to identify the target it hits and to generate and optimize the molecule itself.

Insilico Medicine used one AI platform to rank drug targets and land on TNIK, a protein that had not been taken into clinical testing for lung fibrosis, then used a generative chemistry platform to design a compound against it. Humans still selected, synthesized, tested and optimized the molecules that followed. When the company published its Phase 2a results in Nature Medicine in June 2025, it noted that no AI-discovered drug had yet made it through a Phase 3 trial. This program is now in one.

There is no diabetes anywhere in this story. It is worth following anyway. “AI is going to speed up drug discovery” has been said to people with chronic conditions for years, and this is among the first programs far enough along to check the claim against something real.

ONE DRUG, FIVE YEARS

How rentosertib got this far

Tap a stage to see how it developed.

Insilico’s target discovery platform ranked TNIK as its top candidate for idiopathic pulmonary fibrosis, a target that had never been taken into clinical testing for that disease. Its generative chemistry platform then designed the molecule. The company reports 18 months from the start of target discovery to naming a preclinical candidate.

What the Phase 2a trial showed

The Phase 2a trial, published in Nature Medicine in June 2025, randomized 71 adults with idiopathic pulmonary fibrosis to one of three rentosertib doses or placebo for 12 weeks. Insilico Medicine, which developed the drug, sponsored the trial, and company employees were among the researchers who designed the study and analyzed and interpreted the data. That is worth knowing before reading any of the numbers.

The primary endpoint was safety, not benefit. Lung function was a secondary measure: the 60 mg once-daily group gained a mean of 98.4 mL of forced vital capacity over 12 weeks while the placebo group lost 20.3 mL. The uncertainty was wide: the 95% confidence interval around the high-dose group’s mean change runs from 10.9 to 185.9 mL. That is a within-group estimate, not a confidence interval for the treatment effect against placebo, and this small safety-focused trial was never designed to establish efficacy. Sixteen of the 71 patients stopped treatment before week 12. Liver injury or dysfunction accounted for seven of those sixteen, and four of those seven were also taking nintedanib, an existing antifibrotic. The authors list the limits themselves: small arms, all participants in China, 12 weeks. One early trial does not settle whether AI changed anything. The pattern across the field is more informative.

CHECKING THE CLAIM

Where AI has delivered, and where it hasn’t

Depth is an editorial rating of how much evidence exists, not of how well anything works: 3 = multiple published analyses, 2 = one analysis plus peer-reviewed critique, 1 = review articles proposing directions.

Tap an option. The bars show how much research exists — not how well anything works.

Editorial evidence depth Pipeline analysis

Getting into humans

The clearest signal is that AI is good at producing molecules the body tolerates.

  • A 2024 review in Drug Discovery Today analyzed the clinical pipelines of AI-native biotech companies and found AI-discovered molecules succeeded in Phase 1 at 80-90%, above historic industry averages.
  • The authors read that as evidence the algorithms are capable of designing molecules with drug-like properties.
  • The review was written by consultants at Boston Consulting Group and covers a small number of programs. It is a survey of pipelines, not a controlled comparison.
  • A 2026 Perspective in Nature Reviews Drug Discovery cautions that this apparent Phase 1 advantage rests on few data points, and that most of the programs behind it are built on established disease biology and chemistry, which lowers safety risk independently of AI.

The argument underneath all of this

The real question is not whether the software works. It plainly produces molecules, and those molecules keep clearing Phase 1. The question is which part of drug development was the bottleneck to begin with.

Two readings of the same evidence, both held by serious people:

THEORY 1 The slow part was chemistry

Finding and optimizing a molecule used to take years of synthesis and screening. Insilico reports reaching a preclinical candidate in 18 months. If chemistry was the real constraint, compressing it pulls in every timeline downstream, and the Phase 1 rates across AI-native companies are the first sign of it.

THEORY 2 The slow part was biology

Picking the right target has always been the hard part, and no platform has yet published evidence that it does that better than people do. The Phase 2 rates reported so far are in line with industry norms, and the 2026 Nature Reviews Drug Discovery Perspective finds no established clinical impact yet. On this reading, AI has sped up a step that was never the reason drugs fail.

Nobody can settle that yet, and the more careful reviewers say so directly. The number of AI-discovered drugs that have reached mid-stage trials is small enough that a couple of readouts would move the percentages noticeably. The 2026 Nature Reviews Drug Discovery Perspective calls this an absence of evidence rather than evidence of absence — not proof that AI fails to help, just no demonstration yet that it does, where it counts. Rentosertib’s Phase 3 runs 52 weeks before anyone sees a result.

Software has gotten much faster at proposing molecules. Nothing yet shows it is better at knowing which biology matters — and that is the step that usually decides whether a drug helps anyone.

An editorial read of the evidence

What this means if you live with type 1

Practically, nothing changes today. Rentosertib is being tested in a lung disease, is not approved anywhere, and has no application to diabetes. The useful part is calibration. When a headline says AI designed a drug, what has been demonstrated so far is a faster front end — target to candidate to first-in-human — not a faster or surer path through the trials that determine whether it helps.

That distinction lands harder in type 1 than in most conditions. Speeding up molecule discovery addresses one part of the problem, and the Diabetologia review lists the others: long and expensive trials, difficulty predicting who will progress, responses that vary widely between people, imperfect disease models, and unsettled endpoints. The same review notes that teplizumab, the first therapy approved for delaying type 1 diabetes, took about 30 years of testing to reach approval, including a Phase 2 trial that ran close to a decade. Cutting discovery from years to months does not shorten a trial that has to run long enough to see whether beta cells hold. It is reasonable to find this encouraging and still expect the same waiting. And if a product, test, or supplement is being sold to you on the strength of being AI-designed, that phrase describes how it was made, not what it has been shown to do. Talk with your doctor before making any changes to your care.

Sources. This post started from the September 2026 Nature Biotechnology aging-clock paper on rentosertib, which is used here only as a marker of where the program stands. Peer-reviewed research is used where available; current trial status and company pipeline events are identified as company disclosures. Xu Z, Ren F, Wang P, et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial Nature Medicine, June 2025. Funded and run by Insilico Medicine, which developed the drug; company authors were involved in trial design, analysis and interpretation.

AI-discovered drugs in the clinic. Kp Jayatunga M, Ayers M, Bruens L, Jayanth D, Meier C. How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons Drug Discovery Today, 2024. Authors are consultants at Boston Consulting Group. Retrieved via PubMed.

Discovery and Phase 1. Ren F, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models Nature Biotechnology, published online March 2024. Insilico Medicine authors.

Aging-clock analysis. Zhavoronkov A, Galkin F, et al. Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment Nature Biotechnology, September 2026. Insilico Medicine authors; exploratory analysis of 42 consenting trial participants.

Type 1 diabetes. Retrieved via PubMed. Shapiro MR, Tallon EM, Brown ME, Posgai AL, Clements MA, Brusko TM. Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes Diabetologia, 2025;68(3):477-494 (published online December 2024).

Phase 3 first dosing. Insilico Medicine, Insilico Medicine doses first patient in GENESIS-IPF-3, company announcement, September 9, 2026 (NCT07687459 / CTR20262475). Trial size, center count and duration are as stated by the company.

The wider field, 2026. Bender A, Thomas MC, Scannell JW, et al. Artificial intelligence in drug discovery — what it is, where we stand and the path forward Nature Reviews Drug Discovery, August 2026. Peer-reviewed Perspective; academic and industry authors.

How to read this evidence. The Phase 2a trial is randomized and placebo-controlled, the strongest design here, but it was powered for safety rather than benefit, ran 12 weeks, and enrolled 71 people at sites in one country. The pipeline analysis is a survey of company pipelines rather than a controlled comparison, and its authors flag the small sample behind the Phase 2 figure; the 2026 Nature Reviews Drug Discovery Perspective is a peer-reviewed critique of that same evidence base. The aging-clock analysis is exploratory; its authors state plainly that they cannot separate aging effects from the drug’s anti-fibrotic activity within a fibrosis cohort. Rentosertib is an investigational drug. It is not FDA approved, not approved for any use in the United States, and has no indication in diabetes.

This post is for educational purposes only and is not medical advice. Nothing here is a recommendation to start, stop, or change any medication. Talk with your doctor before making any changes to your care.
One-page version · Juicebox Podcast

An AI-designed drug reached Phase 3

The first patient was dosed in a Phase 3 trial of rentosertib on September 9, 2026. AI systems were used to pick its target and to design the molecule. It is being tested in a lung disease, not diabetes, and it is not approved anywhere.

What the research shows

  • A randomized trial of 71 patients over 12 weeks, published in Nature Medicine in 2025, was designed to test safety. Side-effect rates were similar across the drug and placebo groups.
  • Lung function was a secondary measure in that trial: the highest-dose group gained an average 98.4 mL while placebo lost 20.3 mL. The interval around that gain (10.9 to 185.9 mL) is a within-group estimate, not a comparison against placebo.
  • A 2024 review in Drug Discovery Today found AI-discovered molecules clear Phase 1 at 80-90%, above industry norms, but succeed in Phase 2 at about 40%, the same as everyone else.
  • Insilico Medicine, which developed the drug, sponsored the trial, and company employees were among those who designed and analyzed it.

What it does not show

  • Anything about diabetes. Rentosertib is investigational, is not FDA approved, and has no diabetes indication.
  • That AI picks better targets. Phase 2 is where drugs usually fail, and a 2026 Nature Reviews Drug Discovery Perspective finds no established clinical impact from AI yet.
  • Long-term safety. In the trial, 16 of the 71 patients stopped early; liver injury or dysfunction accounted for seven of them.

If you live with type 1

  • What AI has sped up is the front end: choosing a target and designing a molecule. The company reports 18 months from starting target discovery to naming a candidate.
  • Faster discovery fixes one bottleneck. A 2025 Diabetologia review lists the others: long trials, hard-to-predict progression, varied responses, imperfect models, unsettled endpoints. Teplizumab took about 30 years to reach approval.
  • No AI-designed molecule is in type 1 trials. That same review reported none of the repurposing candidates it surfaced were in a registered type 1 diabetes trial at the time of writing.
  • “AI-designed” describes how something was made, not what it has been shown to do.
Sources. Xu Z, et al. Nature Medicine, 2025 (Insilico-sponsored) · Bender A, et al. Nature Reviews Drug Discovery, 2026 · Kp Jayatunga M, et al. Drug Discovery Today, 2024 · Shapiro MR, et al. Diabetologia, 2025 · Zhavoronkov A, et al. Nature Biotechnology, 2026. Full citations and evidence notes are in the complete post.
Educational purposes only, not medical advice. Nothing here is a recommendation to start, stop, or change any medication. Talk with your doctor before making any changes to your care. juiceboxpodcast.com

Share this

Makes a 9:16 card for Stories, Reels or a text message. Pick a look, then send it straight from supported phones — nothing is uploaded, and you don’t have to save it first.

Shareable card summarizing this post, sized for Instagram or TikTok stories
Save image

Tap a color above to restyle the card. On a phone you can also press and hold the image to save it.

Listen to the Juicebox Podcast

Conversations about diabetes, five days a week, since 2015.

The content on this site is for educational purposes only and is not medical advice.
Read the full disclaimer
© 2007–2026 Juicebox Podcast. All rights reserved.
Read More
Scott Benner Scott Benner

Two Different Roads Into Type 1

Two Different Roads Into Type 1 | Juicebox Podcast
From the Juicebox Blog

Two Different Roads Into Type 1

A genome study split type 1 diabetes by a genetic marker almost nobody has had tested. The two halves turned out to look less alike than expected.

Scott Benner · September 2026

Short on time, or sharing this with someone?

Researchers at the University of Exeter and UC San Diego did something with type 1 genetics that had not been done before. Writing in Diabetologia on August 31, 2026, they took 9,091 people with type 1 and 14,157 people without it, sorted everyone by which high-risk HLA haplotype they carried, and ran the genetics separately in each group. The paper is open access.

Two haplotypes do most of the heavy lifting in type 1 risk. They are called DR3 and DR4, and by the researchers' own accounting roughly 90% of people of European ancestry who develop type 1 carry one or both. Which one a person carries tracks loosely with which islet antibody shows up first, and with how old they are at diagnosis.

Compared side by side, the two groups shared less genetic ground than the researchers expected. That result did not appear out of nowhere. It has been assembling for about a decade, in three other places first.

How this idea built

Four studies, pointing the same direction

Tap a stage to see how it developed.

The TEDDY study followed 8,503 children from birth. Of the 549 who developed islet antibodies, insulin antibodies alone peaked within the first year of life and then declined, while GAD antibodies alone rose until the second year and stayed roughly flat after that. GAD-first was more common in DR3/3 children and less common in DR4/8 children. Two different clocks, watched in real time from birth.

How big a gap is 0.68?

A genetic correlation of 1.0 would mean the measured genetic effects in the two groups line up almost perfectly. The team ran two comparisons as a yardstick. Splitting the same people by sex gave 0.88. Splitting them by whether they were diagnosed before or after age 8 gave 0.96 — close to no genetic difference at all.

Against those, 0.68 is a real separation, and the paper notes it sits near the correlation between Crohn's disease and ulcerative colitis. Worth being precise: the gap against the age split cleared statistical significance, and the gap against the sex split fell just short of it. Worth naming plainly: this work had industry funding alongside its university, government and nonprofit support. It received research funding from Randox Laboratories, and the lead author’s PhD studentship is funded by Randox — a diagnostics company that two of the authors hold a separate grant with, to develop a type 1 genetic risk score biochip. Several authors also disclose consulting or honoraria relationships with pharmaceutical companies.

One locus separated cleanly. Variants near IL2, a gene central to T cell activation, had a larger effect in DR4 carriers than in DR3 carriers, and it was the only locus to survive correction for multiple testing. Three others showed weaker signals that did not. Where the pattern gets broader is in which cellular machinery each group's variants landed in — and putting three groups side by side, a gradient appears.

Three groups, three pictures

Where each group's risk variants point

Tap an option. The bars show how much research exists — not how well anything works.

The question underneath

There is a tension inside this paper worth sitting with. The framework most of this work rests on defines its two groups by age at diagnosis. But when this study split people that way, the genetic correlation came back at 0.96 — the two age groups looked nearly identical. Splitting by HLA produced the wider gap.

Which raises a question the field has not settled: which measurement is doing the real work?

This is the framework built from pancreas tissue. Children diagnosed before 7 show one pathology; those diagnosed after 12 show another. That evidence is direct rather than inferred — someone looked at the tissue. Age is also free, universal, and already sitting in every chart, which makes it usable in a way a genetic test is not.

An editorial read of the new findings would flip the order. Age at diagnosis may describe how fast the process ran rather than which process ran. HLA type is fixed at conception, never drifts, cannot go transiently undetectable the way an antibody can, and in this study separated the genetics more sharply than age did. The paper's own recommendation is that future trials consider DR3 and DR4 status in their design.

The researchers are direct about the limits, and their list is the most useful part of the paper. HLA type is only a partial stand-in for which antibody appears first. Everyone carrying both DR3 and DR4 was left out entirely, because they cannot be assigned to one group — and that combination carries the highest risk of all. The study ran only in people of European ancestry, so how well the findings generalize to other ancestry groups is not yet known. And the mast cell result rests on a single comparison that barely cleared its threshold.

Almost nobody living with type 1 knows their HLA type. It does not appear on a discharge summary, it never changes, and it may turn out to matter.

An editorial observation

What this changes right now

Nothing, for anyone's day-to-day management. HLA typing is not part of routine type 1 care, no treatment decision currently depends on it, and nothing in this paper is approved as a way to choose a therapy. Insulin, pump settings, and CGM alarms are untouched by any of this. It is a study about where the disease comes from, not about how to manage it.

Where it could land is in trial design. If prevention studies start recording HLA background and reporting results by group, the field would learn faster why a drug helps one family and not another — which is the authors' own recommendation.

There is also a smaller group with a more immediate stake: the roughly 10% who carry neither haplotype, are diagnosed later, have fewer detectable antibodies, and sometimes get labeled type 2 for years before anyone revisits it. Anyone who has wondered whether their own diagnosis got sorted into the wrong bin has a reasonable question to raise — not a demand for a genetic test, but a conversation about what was measured and when. That is a conversation to have with a doctor who knows the whole history, not a decision to make from a study.

Sources. This post was built from the primary literature, starting with the open-access Diabetologia paper and tracing every supporting claim to the study behind it. Every claim above is cited to the underlying research rather than to the report:

The main study. Luckett AM, McGrail C, Murrall K, et al. Genetic association stratified by HLA-DR3 and HLA-DR4 status reveals heterogeneity in pathways of progression to type 1 diabetes. Diabetologia, 31 August 2026. Open access. Funded by university, government and nonprofit sources, plus research funding from Randox Laboratories; the lead author holds a Randox PhD studentship, and two authors hold a Randox grant to develop a type 1 genetic risk score biochip. Authors separately disclose consulting and honoraria relationships with several pharmaceutical companies.

People with neither haplotype. McGrail C, Chiou J, Elgamal R, et al. Genetic discovery and risk prediction for type 1 diabetes in individuals without high-risk HLA-DR3/DR4 haplotypes. Diabetes Care 2025;48(2):202–211.

Antibody order in children. Krischer JP, Lynch KF, Schatz DA, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 2015;58(5):980–987.

Pancreas tissue and age at diagnosis. Leete P, Oram RA, McDonald TJ, et al. Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis. Diabetologia, 2020.

Mast cells in donated pancreas tissue. Martino L, Masini M, Bugliani M, et al. Mast cells infiltrate pancreatic islets in human type 1 diabetes. Diabetologia 2015;58(11):2554–2562.

IL2 and age at diagnosis. Howson JMM, Cooper JD, Smyth DJ, et al. Evidence of gene-gene interaction and age-at-diagnosis effects in type 1 diabetes. Diabetes 2012;61(11):3012–3017.

Teplizumab subgroups. Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. New England Journal of Medicine 2019;381(7):603–613. Subgroup findings were prespecified but not adjusted for multiple comparisons.

How to read this evidence. Every study above is a genetic association or tissue study, not a test of a treatment. They describe patterns across large groups of people; none of them predicts what will happen to any one person. Association is not cause: finding that a variant is more common in a group does not show that it drives the disease. The teplizumab subgroup numbers come from prespecified analyses that were not adjusted for multiple comparisons and have been described in the literature as exploratory. HLA typing is not part of standard type 1 care, and no therapy is approved to be selected on the basis of DR3 or DR4 status.

This post is for educational purposes only and is not medical advice. Nothing here is a recommendation to start, stop, or change any medication. Talk with your doctor before making any changes to your care.

Two Different Roads Into Type 1

A genome study split type 1 by HLA background and found the two groups less genetically alike than expected. It is a study about where the disease comes from, not about how it is managed, and nothing in it changes anyone’s care.

What the research shows

  • Luckett et al., Diabetologia, August 2026: 9,091 people with type 1 and 14,157 without, sorted by whether they carried the DR3 or the DR4 haplotype. Setting the HLA region aside, the two groups’ genetic effects correlated at 0.68.
  • Splitting the same people by age at diagnosis gave 0.96, and by sex 0.88. The gap against the age split cleared statistical significance; the sex gap fell just short.
  • DR4 risk variants clustered in T cell machinery. DR3 variants clustered in mast cell regulatory regions and pathways for secretion and cellular stress.
  • IL2 was the only locus whose difference between groups survived correction for multiple testing.
  • A companion study (McGrail et al., Diabetes Care, 2025) found the roughly 10% who carry neither haplotype lean toward antigen presentation, innate immunity and beta cell pathways instead.

What it does not show

  • Not a new diagnosis, subtype or test. No category changed and no one’s care changes because of it.
  • Everyone carrying both DR3 and DR4 was excluded, because they cannot be assigned to one group — and that combination carries the highest risk of all.
  • The study ran only in people of European ancestry, so how well the findings generalize to other ancestry groups is not yet known.
  • The mast cell result rests on a single comparison at p=0.043. A lead, not a finding.
  • These are association studies. Finding a variant more often in a group does not show that it drives the disease.

If you live with type 1

  • HLA typing is not part of routine type 1 care, and no treatment decision currently depends on it.
  • The likely near-term consequence is trial design — recording HLA background and reporting results by group, which is the authors’ own recommendation.
  • If your own diagnosis was ever unclear — later onset, few detectable antibodies, an initial type 2 label — that is a reasonable thing to raise with the doctor who knows your whole history.
Sources. Luckett AM, et al. Diabetologia, 2026 · McGrail C, et al. Diabetes Care 2025;48(2):202–211 · Krischer JP, et al. Diabetologia 2015;58(5):980–987 · Leete P, et al. Diabetologia, 2020 · Martino L, et al. Diabetologia 2015;58(11):2554–2562 · Howson JMM, et al. Diabetes 2012;61(11):3012–3017 · Herold KC, et al. NEJM 2019;381(7):603–613.

Funding. The main study had industry funding alongside university, government and nonprofit support, including research funding and a PhD studentship from Randox Laboratories.

Educational purposes only and not medical advice. Talk with your doctor before making any changes to your care. — juiceboxpodcast.com

Share this

Makes a 9:16 card for Stories, Reels or a text message. Pick a look, then send it straight from your phone — nothing is uploaded, and you don’t have to save it first.

Shareable card summarizing this post, sized for Instagram or TikTok stories
Save image

Tap a color above to change the card. On a phone you can also press and hold the image to save it.

Listen to the Juicebox Podcast

Conversations about diabetes, five days a week, since 2015.

The content on this site is for educational purposes only and is not medical advice.
Read the full disclaimer
© 2007–2026 Juicebox Podcast. All rights reserved.
Read More